LAVA Therapeutics N.V. was incorporated in the Netherlands on February 15, 2016. The company is a clinical-stage immuno-oncology company dedicated to the rapid development of new cancer treatments that harness the immune system to save patients' lives. Utilizing the company's Gammabody platform, the company is developing a series of novel bispecific antibodies designed to harness the potency and precision of γ-δ (gd) T cells to elicit a powerful natural anti-tumor immune response and improve the prognosis of cancer patients. 

LVTX(Delisted)

LVTX Profile